Safe Biologics

APRIL 25, 2023

By Michael Reilly, Executive Director, Alliance for Safe Biologic Medicines (ASBM) ASBM recently submitted comments to the Centers for Medicare & Medicaid Services (CMS) on the proposed Medicare Drug Price Negotiation Plan. First, the policy itself has built-in-problems. 2 Furthermore, cancer death rates per 100,000 are 1.6

Drug Pricing 130

Drug Pricing Biosimilars Vaccines 130

Safe Biologics

APRIL 25, 2023

By Michael Reilly, Executive Director, Alliance for Safe Biologic Medicines (ASBM) ASBM recently submitted comments to the Centers for Medicare & Medicaid Services (CMS) on the proposed Medicare Drug Price Negotiation Plan. First, the policy itself has built-in-problems. 2 Furthermore, cancer death rates per 100,000 are 1.6

Drug Pricing 130

Drug Pricing Biosimilars Vaccines 130

pharmaphorum

APRIL 13, 2022

The reason a price cap is being targeted is due to the rapid increase in the cost of insulin products over the last few decades. According to research , one vial of Humalog (insulin lispro) cost $21 in 1999, but this increased to $332 in 2019, representing a price increase of 1480%.

Drug Pricing 130

Drug Pricing Diabetes Biosimilars 130

STAT

OCTOBER 4, 2023

A company called Bluebird Bio won European approval in 2019 for a gene therapy for thalassemia, a cutting-edge medicine that involves delivering a healthy copy of the gene that’s mutated in patients directly into their cells. A few years ago, the chance for a post-thalassemia life seemed within reach.

Drug Pricing 362

Drug Pricing 362

STAT

SEPTEMBER 27, 2023

The New Jersey Democrat has long been an outspoken ally for the industry, sometimes even diverging with his party to shield drugmakers from pricing reforms. In a heated 2019 bill markup, he joined Republicans in voting against amendments to introduce price-hike caps and drug price negotiation in Medicare.

Drug Pricing 265

Drug Pricing Diabetes 265

STAT

OCTOBER 31, 2023

Later, Amgen reworked old patent applications and, by doing so, succeeded in extending patent protection for the medicine from 2019 until 2029, according to an analysis by the advocacy group. Continue to STAT+ to read the full story…

Drug Pricing 330

Drug Pricing 330

STAT

SEPTEMBER 15, 2022

In a victory for Gilead Sciences, Brazilian antitrust authorities dismissed a complaint filed by several advocacy groups that alleged the company charged “abusive” prices for a hepatitis C treatment.

Documentation 246

Documentation Drug Pricing 246

STAT

SEPTEMBER 23, 2022

billion in 2020 (three times higher than savings from 2019) and have the potential to increase to $133 billion by 2025. Generic & Biosimilar Medicines Savings Report” from the Association for Accessible Medicines, biosimilar savings in the U.S. Read the rest…

Biosimilars 246

Biosimilars Diabetes Drug Pricing 246

RX Note

APRIL 16, 2023

Why Drug Prices Are Rising? Newly developed drugs can be expensive to produce. During patent exclusivity, prices are set higher to offset the high research and development cost (up to billions of dollars). Confidential price discounts prevents everyone from demanding the lowest available price.

Drug Pricing 40

Drug Pricing Documentation Pharmaceutical Companies Pharmaceutical Companies 40

European Pharmaceutical Review

JANUARY 2, 2024

According to results from a survey by GlobalData, the top challenges for the pharmaceutical industry in 2024 will be inflation, geopolitical conflict and drug pricing pressures. Data outcomes revealed that most respondents from Pharma considered that drug pricing and reimbursement constraints will have a negative impact in 2024.

Drug Pricing 102

Drug Pricing Drug Development 102

pharmaphorum

JANUARY 16, 2023

” First introduced in 2019, the VPAS was designed to provide a guarantee that the NHS will not spend more than 2% more a year on branded medicines, with the industry returning any spending beyond the cap in the form of a levy. . ” The post AbbVie, Lilly pull out of UK voluntary drug pricing agreement appeared first on.

Drug Pricing 69

Drug Pricing 69

Drug Channels

JULY 6, 2020

It’s the 11th edition of our popular and comprehensive examination of the entire drug pricing, reimbursement, and dispensing system. prescription dispensing revenues for calendar year 2019. As you will see, pharmacy industry prescription dispensing revenues reached a record $446 billion in 2019.

Specialty Pharmacies 40

Specialty Pharmacies Drug Pricing 40

Drug Channels

JULY 6, 2020

It’s the 11th edition of our popular and comprehensive examination of the entire drug pricing, reimbursement, and dispensing system. prescription dispensing revenues for calendar year 2019. As you will see, pharmacy industry prescription dispensing revenues reached a record $446 billion in 2019.

Specialty Pharmacies 40

Specialty Pharmacies Drug Pricing 40

Drug Channels

SEPTEMBER 22, 2021

Despite what you may have heard, the 340B Drug Pricing Program continues to thrive. That figure is an astonishing 27% higher than its 2019 counterpart—and more than quadruple the value of discounted purchases in 2014. Click here to see the original post and comments from June 2021.

Drug Pricing 45

Drug Pricing Hospitals 45

NY Times

MARCH 24, 2021

The pharmaceutical industry doesn’t want things to change, but Americans can have both lower prices and innovation.

Drug Pricing 73

Drug Pricing Immunization Immunity Vaccines 73

Drug Channels

JUNE 16, 2021

Despite what you may have heard, the 340B Drug Pricing Program continues to thrive. That figure is an astonishing 27% higher than its 2019 counterpart—and more than quadruple the value of discounted purchases in 2014. Discounted purchases under the program reached at least $38 billion in 2020.

Drug Pricing 40

Drug Pricing Hospitals 40

Drug Channels

JUNE 9, 2020

The 340B Drug Pricing Program has logged another year of incredible growth. According to data provided to Drug Channels by the Health Resources and Services Administration (HRSA), discounted 340B purchases were at least $29.9 billion in 2019. That figure is an astonishing 23% higher than its 2018 counterpart.

Drug Pricing 40

Drug Pricing Hospitals 40

HealthPartners

MAY 5, 2021

Understanding pharmacy benefit management and drug pricing The U.S. prescription drug supply chain is extraordinarily complex. It captures, with strong simplification, the web of stakeholders in the prescription drug market and the myriad of contractual agreements that drives the cash flows between them.

Drug Pricing 40

Drug Pricing Mail-Order Pharmacies Pharmaceutical Manufacturing Pharmaceutical Companies 40

Putting Patients First Blog

NOVEMBER 14, 2023

NHC Comments on Request for Information: Medicare Transaction Facilitator (MTF) for the Medicare Drug Price Negotiation Program (PDF) November 13, 2023 Benjamin Stidham, Contract Specialist Centers for Medicare & Medicaid Services U.S. Drug Distribution Data 2019. Drug Distribution Data 2019. Blendon, R.,

Drug Pricing 40

Drug Pricing Specialty Pharmacies HIPAA Payment Processing 40

pharmaphorum

DECEMBER 24, 2020

Reviewing 2019’s key digital health stories last year I suggested that, while big strides continued to be made, any definitive ‘coming of age’ moment for the sector was unlikely. Consequently, what might previously have looked upon as a 3, 5 or even 10 year plan suddenly required progress within just days or weeks.

Drug Pricing 126

Drug Pricing Communication 126

pharmaphorum

DECEMBER 7, 2022

Having recently assessed the relationship between drug price and prevalence of non-oncology rare diseases, CRA’s Life Sciences Practice team explores in greater depth the situation for these orphan drugs in France in this final article of a three-part series. Influence of ATUc programme on drug pricing.

Drug Pricing 105

Drug Pricing Drug Development 105

Drug Channels

AUGUST 11, 2020

Time for our annual update on pricing at five of the largest pharmaceutical manufacturers—Eli Lilly, Janssen, Merck, Novartis, and Sanofi. When rebates and discounts were factored in, drug prices declined—or grew slowly—in 2019. d/b/a Drug Channels Institute. You can find links to each company’s data below.

Drug Pricing 52

Drug Pricing Pharmaceutical Manufacturing 52

pharmaphorum

JANUARY 14, 2021

US cost effectiveness watchdog ICER found 10 examples of substantial price rises for top-selling medicines in 2019, and concluded that seven of those were not backed by any clinical evidence. That also identified seven hefty price hikes for products – including Humira and Tecfidera – but cumulatively they all added a massive $4.8

Drug Pricing 59

Drug Pricing 59

Pharmaceutical Technology

SEPTEMBER 15, 2022

According to GlobalData’s report, Coronavirus Disease 2019 (Covid-19) Analyst Consensus Sales Analysis and Forecast, H1 2022 , Comirnaty is the leading prophylactic Covid-19 vaccine and recorded sales of $41.3bn in 2021.

Vaccines 108

Vaccines Drug Pricing Biosimilars Documentation 108

Drug Channels

JULY 21, 2020

pharmacies now participate in the 340B Drug Pricing Program. We estimate that specialty pharmacy dispensing accounted for nearly one-third of PBMs’ total gross profits in 2019. Last week, I documented that nearly half of U.S. Below, we update our exclusive analysis of the biggest specialty pharmacies within 340B.

Specialty Pharmacies 52

Specialty Pharmacies Drug Pricing Documentation Hospitals 52

pharmaphorum

JANUARY 13, 2023

The complaint – which comes as insulin has become the focal point of the drug pricing debate in the US – alleges that Novo Nordisk, Lilly, and Sanofi “aggressively raised the list price of insulin in lockstep with each other.”

Diabetes 105

Diabetes Drug Pricing Biosimilars 105

Drug Channels

APRIL 26, 2021

It explores: How systemic inefficiencies mean patients pay more for drugs Why past drug price interventions have failed the patients who need them most The tech-enabled, data-driven way to fix drug distribution and put patients first The report also includes never-before-published insights leveraged from Kalderos’ proprietary data, drawing on our tech-enabled (..)

Drug Pricing 52

Drug Pricing 52

Putting Patients First Blog

JULY 2, 2024

General Comments The NHC appreciates CMS’ commitment to actively engaging with stakeholders, including patients, consumer advocates, and health experts, in implementing the Medicare Drug Price Negotiation Program (DPNP). This includes collecting data on utilization management practices, formulary changes, and patient experiences.

Drug Pricing 52

Drug Pricing Insurance Coverage and Processing Labelling HIPAA 52

Pharmaceutical Technology

MARCH 10, 2023

Consequentially, the five-year average price trend in Lebanon for all medicines has increased to 1,123%. GlobalData reviews the key events leading up to these current price trends in Lebanon. As this reduction of subsidies coincided with the weakening of the Lebanese pound, it resulted in further heavy price increases.

Drug Pricing 52

Drug Pricing Packaging 52

pharmaphorum

JUNE 4, 2021

In fact, the four million increase is at the top end of normal increases in prescription antidepressant use in England, which have typically increased by three to four million per year, although monthly spending on these drug by NHS England has tended to decrease.

Drug Pricing 98

Drug Pricing 98

pharmaphorum

SEPTEMBER 8, 2020

6 Forbes, ‘Biologic Medicines: The Biggest Driver of Rising Drug Prices’. Published 8 March 2019. 9 US Food and Drug Administration, ‘statement on efforts to help make development of biosimilar and interchangeable insulin products more efficient’. Published 25 November 2019. Published 17 September 2018.

Biosimilars 99

Biosimilars Drug Pricing Chemotherapy Vaccines 99

FDA Law Blog: Biosimilars

SEPTEMBER 23, 2024

Hatch Foundation’s For cheap generic drug prices, you can thank 40 years of Hatch-Waxman We Work For Health’s Hatch-Waxman Act: Celebrating 40 Years of a Balanced and Innovative Drug Ecosystem Tradeoffs’ Race to the Bottom Series FDA CDER Conversations – 40th Anniversary of the Generic Drug Approval Pathway The U.S.

Dosage 59

Dosage Drug Pricing 59

European Pharmaceutical Review

JUNE 24, 2022

The review was impacted by Brexit and the COVID-19 pandemic, which compounded existing issues surrounding high drug pricing and patient access that had been brewing since 2016 and highlighted several shortcomings in the EU’s pharmaceutical system. pocket expenses account for only seven percent of the overall cost of developing drugs.

Compounding 105

Compounding Drug Development Drug Pricing Dosage 105

European Pharmaceutical Review

SEPTEMBER 14, 2023

Market uncertainty Rising operational costs, stiffening competition, ongoing patent expirations, evolving environmental and social governance requirements and increasing pressure on drug prices mean the industry will have to navigate thoughtfully to be successful amid this complicated mix of financial and strategic risks.

Drug Development 98

Drug Development Drug Pricing Communication 98

Pharmaceutical Technology

SEPTEMBER 22, 2022

Invossa has demonstrated the efficacy and safety of a single shot for up to three years, as outlined by Lew in a 2019 study published in Osteoarthritis and Cartilage (NCT03383471). These are TissueGene’s Invossa and Organogenesis Holdings’ ReNu, both of which have shown disease-modifying efficacy in clinical trials.

Drug Pricing 59

Drug Pricing Diabetes 59

PharmaState Academy

OCTOBER 20, 2023

a) It can support market access by demonstrating real-world benefits b) It doesn't play a role in market access c) It increases market competition d) It leads to market exclusivity 2 / 20 According to a 2019 report by the U.S.

Drug Pricing 104

Drug Pricing 104

pharmaphorum

FEBRUARY 18, 2021

Drug prices to plummet in wave of expiring patents”. Price decay after loss of brand exclusivity”. These are just three headlines that come up when you Google “drug patent expiry”. RESULT: Humalog is still Lilly’s second top-selling drug with nearly $3 billion in sales in 2018. “Patent losses could sink Allergan”.

Prescription Filling 52

Prescription Filling Drug Pricing Biosimilars Compounding 52